☆ 4.6 Letter

Long-term cardiovascular burden in prostate cancer patients receiving androgen deprivation therapy

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2023)

Related references

Note: Only part of the references are listed.
Article Peripheral Vascular Disease

Relationship between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and COVID-19 incidence or severe disease

Gary Tse et al.

Summary: The study found a significant relationship between ACEI/ARB use and COVID-19 positivity and severe disease after adjusting for significant confounders. There were no significant differences in COVID-19 positivity or disease severity between ACEI and ARB use.

JOURNAL OF HYPERTENSION (2021)

Add to Collection
Article Oncology

Long-term outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80 years old

Leandro Blas et al.

Summary: This study examined the survival rate and risk of death from prostate cancer in men aged >= 80 y treated with primary androgen deprivation therapy. The findings suggest that immediate ADT may not be necessary for low- and intermediate-risk groups, but more efforts for curative therapy are needed for high- or very high-risk, regional, and metastatic prostate cancer patients.

CANCER SCIENCE (2021)

Add to Collection
Review Hematology

Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses

Jiun-Ruey Hu et al.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2020)

Add to Collection
Article Oncology

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer

Nancy L. Keating et al.

JOURNAL OF CLINICAL ONCOLOGY (2006)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.